Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of IBI306 in healthy subjects
NCT03366688Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- Nov 2017
- Primary completion
- Nov 2018
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in hypercholesterolemia comparing IBI306 with Placebo (2 arms). Primary endpoint: Number of participants with adverse events at 12 weeks. Started Nov 2017; status: completed.
02
Drugs
tafolecimab
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT03366688.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03366688.